Compare · AXGN vs INMD
AXGN vs INMD
Side-by-side comparison of Axogen Inc. (AXGN) and InMode Ltd. (INMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and INMD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.68B, about 3.1x INMD ($863.9M).
- INMD has been more active in the news (6 items in the past 4 weeks vs 4 for AXGN).
- INMD has more recent analyst coverage (20 ratings vs 8 for AXGN).
- Company
- Axogen Inc.
- InMode Ltd.
- Price
- $49.91+1.52%
- $15.03-0.46%
- Market cap
- $2.68B
- $863.9M
- 1M return
- -
- -2.31%
- 1Y return
- -
- +1.08%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 4
- 6
- Recent ratings
- 8
- 20
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Latest AXGN
- EVP & General Counsel Began Marc A exercised 67,500 shares at a strike of $8.16 and sold $3,195,788 worth of shares (67,500 units at $47.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wendell Amy Mcbride exercised 13,353 shares at a strike of $14.85 and sold $646,592 worth of shares (13,353 units at $48.42) as part of a pre-agreed trading plan (SEC Form 4)
- Director Weiler Kathy Johnson sold $640,967 worth of shares (14,150 units at $45.30) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- SEC Form 10-Q filed by Axogen Inc.
- Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
- Axogen, Inc. Reports Second Quarter 2026 Financial Results
- Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
- Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Latest INMD
- SEC Form 6-K filed by InMode Ltd.
- Chief Financial Officer Itzkovich Moshe was granted 14,000 units of Ordinary Shares, increasing direct ownership by 57% to 38,430 units (SEC Form 4)
- SEC Form 6-K filed by InMode Ltd.
- InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- SEC Form 6-K filed by InMode Ltd.
- Director Kenneth Nadav was granted 2,000 units of Ordinary Shares, increasing direct ownership by 67% to 5,000 units (SEC Form 4)
- Director Nass Shlomo was granted 2,000 units of Ordinary Shares (SEC Form 4)
- Director Ron Hadar was granted 2,000 units of Ordinary Shares, increasing direct ownership by 3% to 60,270 units (SEC Form 4)
- Steel Partners Urges InMode Shareholders to Vote AGAINST the Re-Election of Dr. Hadar Ron and AGAINST Extraordinary Special Committee Compensation at the July 30 Annual General Meeting